ARTICLE | Clinical News
Davunetide: Additional Phase IIa data
December 21, 2009 8:00 AM UTC
Updated data from a double-blind, U.S. Phase IIa trial in 54 schizophrenics showed that 5 mg intranasal davunetide met the secondary endpoint of significantly improving baseline functional capacity of...